Restless
legs syndrome or RLS is a neurological disease. RLS is also called as
Willis-Ekbom disease. Patients suffering from RLS disease have an irresistible
desire to move their feet. The continual movement of the legs leads to pain in
the limbs, which leads to the unusual sleep pattern of patients.
The exact
reason behind the restless
legs syndrome is not known precisely, however, it is believed the
disease is caused due to genetic factors or due to iron deficiency in the brain
or due to the disorders in dopaminergic balance.
The exact
treatment of this disease is not present till now. However the available drug
in the market helps in the indicative treatment of the disease. Some of the
drug in the restless legs syndrome market such as sulfonamide by safinamide by
Newron Pharmaceuticals reduces the symptoms by novel action such as potent,
reversible and selective inhibition of MAO-B, without disturbing the MAO-A and
dopamine uptake. This enhances the glutamate release and dopaminergic function
of the patients; it also reduces the dopamine degradation. One other drug:
SER-214 manufacture by Serina is used widely in the restless legs syndrome
treatment; it uses a water-soluble polymer poly (2-alkyloxazoline)-based drug
delivery technology this drug can be combined with the polymer and transported
to the patients.
Request to Get the
Sample Pages at:
Based on
the different product type the global restless legs syndrome market can be
broadly classified as Mirapex/Sifrol/Mirapexin, Neupro/Leganto, Requip, and
HORIZANT/Regnite. On the basis various disease type the global restless legs
syndrome market can be broadly bifurcated as etiology and pathogenesis, iron
deficiency, genetic factors, neurological disturbances and others. Based on the
mode of the therapy the global restless legs syndrome market can be broadly
segmented into two broad categories: pharmacological therapy and
non-pharmacological therapy.
Make Enquiry Before
Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=restless-legs-syndrome-market
Some of the
major players operating in the global restless legs syndrome market include,
GlaxoSmithKline plc., Ligand Pharmaceuticals Incorporated, axxonis Pharma AG,
Kyowa Hakko Kirin Co., Jazz Pharmaceuticals, Inc., Omeros Corporation,
Manhattan Pharmaceuticals, Boehringer Ingelheim GmbH, UCB SA.
